# 1. Financial Performance ## A. Key Figures * Revenue from Operations: ₹207 Cr (Q1 FY'26) (+17.3% YoY) * **Gross Profit:** **₹110.3 Cr** (+48.4% YoY) · **Gross Margin:** **53.2%** (+1,117 bps YoY) * EBITDA: ₹50.9 Cr (+72.4% YoY) · EBITDA Margin: 24.6% (+785 bps YoY) * PAT: ₹44 Cr (vs. ₹14.7 Cr prior year) · PAT Margin: 21.2% (+1,292 bps YoY) * **Other Income:** **₹16 Cr** (incl. ₹12.5 Cr forex gains, ₹3.5 Cr interest) * **Net Cash & Equivalents:** **₹270 Cr** · **Working Capital:** **128 days** (up 14 days QoQ) ## B. Revenue Growth * **Selective Growth Trajectory:** Top-line expansion driven by **advanced pharmaceutical intermediates**, with steady contribution from specialty chemicals amid seasonally softer Q1 demand. * **Volume and Mix Momentum:** Revenue growth underpinned by **strong volume growth and favorable product mix**, particularly in high-value offerings. ## C. Gross Margin * **Margin Acceleration:** Gross margin surged to 53%, reflecting sustained benefits from **cost optimization and structural improvements in product mix**, especially in flagship products. * **Segment Divergence:** Significant margin gap between **Pharma Intermediates (28%)** and **Specialty Chemicals (11%)**, highlighting differing profitability dynamics across businesses. * **Forward Guidance:** Management expects group-level gross margins to stabilize in the **48–50% range**, though not uniformly across segments. ## D. EBITDA & PAT * **Profitability Leverage:** PAT tripled year-on-year, driven by **expanding EBITDA margins and elevated other income**, notably **foreign exchange gains**. * **Sequential Margin Pressure:** Despite gross margin gains, EBITDA margin declined QoQ due to **higher operating expenses relative to seasonal revenue dip**. ## E. Cash Flow * **Working Capital Build:** Increase in working capital to 128 days reflects **strategic prepayments for raw material cost advantages**, with full-year normalization expected near 110 days. * **Resilient Cash Generation:** Company delivered **positive operating cash flow of ₹6 Cr** despite elevated working capital, underscoring operational efficiency. --- # 2. Segment & Product Performance ## A. Key Figures * Pharma Intermediates Revenue: **₹165.8 Cr** (Q1 FY'26) (+23.3%) * Specialty Chemicals Revenue: ₹41.4 Cr (Q1 FY'26) (flat) ## B. Pharma Intermediates * **Strong Core Growth:** Advanced intermediates delivered robust double-digit growth, driven primarily by non-CDMO business and key products like Apixaban and Rivaroxaban. * **Favorable Mix & Visibility:** Ex-CDMO growth supported by improved margins and long-term visibility, including R&D completion for APIs with patent expiries beyond 2040. * **Fermion & Contract Wins:** Secured long-term contract for a key Fermion product with visibility into 2035; CDMO segment remains strategic with established originator relationships. ## C. Specialty Chemicals * **Margin Trajectory:** Business maintains double-digit EBITDA margins, with meaningful expansion expected by **2027** as higher-margin electrolyte additive segment scales. * **Commodity Strength:** Sub-segment showed healthy growth despite flat overall revenue, indicating positive underlying momentum. ## D. CDMO Projects * **Near-Term Commercialization:** Three CDMO projects on track for commercialization by end-FY'26, with one already supplying validation batches; revenue contribution expected from Q4 FY'26. * **Revenue Potential:** Each new CDMO contract carries **₹50–100 Cr** revenue potential, with combined upside comparable to current CDMO book in 2–3 years. * **Therapy Diversification:** Oncology dominates CDMO pipeline, while non-CDMO spans 17 therapeutic areas; no GLP-1 intermediates, but coupling agents produced. * **Global Expansion in Semiconductors:** Despite soft end-demand, company is gaining traction in Korea, Japan, and Taiwan; JV to bring advanced tech with R&D in Korea. --- # 3. Capacity & Capex ## A. Key Figures * **Capex (Quarter):** ₹69 Cr (electrolyte additives focus) * **Capex (Total FY):** ₹250 Cr estimated (fully cash-funded) * Electrolyte Additives Capex: ₹180 Cr (VC/FEC capacity) · +₹50 Cr incremental (new products) * **Pilot Plant Capex:** ₹30 Cr * **Maintenance Capex:** ₹40 Cr * Indichem JV Investment: ~KRW30 billion (75% funded by company) * Solar Power Capacity: 5 MW newly commissioned, totaling 15.8 MW across Sachin, Ankleshwar, Jhagadia ## B. Electrolyte Additives * **Strategic Entry:** Launching battery chemicals business with **electrolyte additives** as core offering, targeting high-growth EV supply chain. * **Capacity Ramp-Up:** Full commissioning of **2,000 MT each of VEC and FEC** expected by end-FY26, with rapid scale-up in FY27. * **Revenue Timeline:** First revenues from additives and CDMO project expected in **Q4 FY26**, marking commercial inflection. * **Asset Efficiency:** Targeting **5x asset turnover** on electrolyte capex, with margins expected to exceed current specialty chemical businesses. ## C. Pilot & New Plants * **Korea JV Execution Underway:** Indichem plant finalized, with commercial production targeted for **late 2026 or early 2027**. * **New Product Expansion:** Additional capex allocated to support **new additives beyond VC/FEC**, with production start expected by **early 2027**. * **Pilot Progress:** Pilot plant capex initiated at Sachin; completion expected within one year. * **Ankleshwar Capex Complete:** All blocks now commercialized, closing out prior expansion phase. ## D. Asset Turnover * **Cost Advantage:** Solar capacity additions (8 MW total) to deliver full cost savings from **Q3 FY26**, boosting operating efficiency. * **High Return Target:** Battery chemicals business designed for **5x asset turnover** and superior margin profile versus legacy operations. --- # 4. Customer & Geography Mix ## A. Key Figures * JV Investment: KRW 30 billion for Indichem in Korea * **JV Ownership:** **75%** company stake · **25%** Korean partner stake ## B. Export Markets * **Strategic Global Focus:** Export-dedicated capacity with no reliance on Indian domestic demand; initial commercial focus on Korea and Taiwan due to semiconductor cluster proximity. * **Market Expansion:** Advanced customer engagements in **Korea** and **Japan**, with final-stage discussions underway with a large multinational. * **Growth Trajectory:** Addressable market for semiconductor chemicals expected to grow at **double-digit rates**, supported by U.S. manufacturing expansion and global supply chain diversification. * **Segment Clarity:** Japan and Taiwan are customers for semiconductor chemicals, not electrolyte additives—segment remains dominated by Chinese suppliers. ## C. Joint Venture Focus * **Indichem JV Established:** Formed in South Korea to align with customer-driven supply chain diversification, with strong visibility on product mix and confirmed post-commercialization demand. * **Value Exchange:** Korean partner contributes product, technology, and market access in exchange for 25% ownership, enhancing global go-to-market capabilities. --- # 5. Supply Chain & Competition ## A. China Plus One * **Regulatory Catalyst:** The Act restricting foreign entities and phasing out manufacturing credits is driving urgency, resulting in heightened customer interest in the company's battery chemicals. * **Supply Chain Shift:** Battery additive segment positioned to benefit from regulatory-driven diversification, as global manufacturers pursue China Plus One strategies amid Chinese dominance in electrolyte additives. * **Resilient Demand:** Pharma and specialty chemicals businesses remain unaffected by tariffs, with stable pricing and demand trends. ## B. Cost Competitiveness * **Competitive Positioning:** Company asserts it will be **cost-competitive with Chinese producers** upon product launch, underscoring strategic discipline in market entry. --- # 6. Risks & Regulatory Shifts ## A. Regulatory & Compliance Milestones * **Dual Facility Certification Achieved:** Both pharma intermediates facilities now PMDA GMP certified, following virtual audit clearance for Unit II at Ankleshwar. * **Standardized Validation Protocol:** All products—established and new—will undergo **standard validation and qualification procedures**, ensuring regulatory readiness across scales. ## B. Tariff & Export Risks * **Unresolved Tariff Concerns:** Export business exposure to tariff dynamics flagged as a risk, though management’s response to mitigation strategy was not disclosed. --- # 7. Guidance & Outlook ## A. Key Figures * **FY26 Revenue Growth Guidance:** **25%** (maintained) * **Margin Improvement Target:** **50–100 bps** above FY25 full-year levels ## B. FY26 Growth Target * **Confident Growth Trajectory:** Management maintains **25% revenue growth** guidance with strong visibility across pharma intermediates and specialty chemicals, despite softness in the **Baba Fine Chemicals** business. * **Sequential Quarterly Improvement:** Performance expected to improve each quarter, with H2 FY26 benefiting from new project ramp-up, including delayed battery chemicals revenue starting **early next fiscal year**. * **Battery Chemicals Timeline Intact:** Delays by partners like Exide, Amara, Maruti, and Tata Motors do not impact company’s FY27 benefit expectations; revenue from Q4 FY25 project begins in **H2 FY26** pending approvals. ## C. Margin Trajectory * **Progressive Margin Expansion Expected:** Margins anticipated to improve sequentially from Q1 due to scaling sales and **better operating leverage**, supported by ongoing cost optimization. * **Structural Margin Upside:** **CDMO business** carries higher margins than legacy operations, with a shift in revenue mix expected to drive further expansion **from FY27 onwards**. * **Gross Margin Resilience:** Sustained efforts position gross margins to remain **above 50%** in upcoming periods, despite quarterly mix volatility.